Targeting the heat shock protein 90: A rational way to inhibit macrophage migration inhibitory factor function in cancer

Current Opinion in Oncology

Volumn 26, Issue 1, 2014, Pages 108-113

  Schulz, Ramona ^a   Moll, Ute M ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

cancer; heat shock protein 90; macrophage migration inhibitory factor; macrophage migration inhibitory factor inhibition; nononcogene addiction

Indexed keywords

ADENOSINE TRIPHOSPHATASE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOXAZOLINE DERIVATIVE; MACROPHAGE MIGRATION INHIBITION FACTOR; NEUTRALIZING ANTIBODY; TANESPIMYCIN; TRASTUZUMAB;

APOPTOSIS; BLADDER CANCER; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; COLORECTAL CANCER; COMPETITIVE INHIBITION; DIGESTIVE SYSTEM CANCER; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; IMMUNOHISTOLOGY; LIVER CELL CARCINOMA; MACROPHAGE MIGRATION INHIBITION; NEOPLASM; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; SEPSIS; SQUAMOUS CELL CARCINOMA; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MACROPHAGES; MICE; NEOPLASM PROTEINS; NEOPLASMS;

EID: 84890559258     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000036     Document Type: Review

References (69)

1. Grieb G, Merk M, Bernhagen J, Bucala R. Macrophage migration inhibitory factor (MIF): A promising biomarker. Drug News Perspect 2010; 23:257-264.
2. Bucala R, Donnelly SC. Macrophage migration inhibitory factor: A probable link between inflammation and cancer. Immunity 2007; 26:281-285.
3. Conroy H, Mawhinney L, Donnelly SC. Inflammation and cancer: Macrophage migration inhibitory factor (MIF): The potential missing link. Q J Med 2010; 103:831-836.
4. Calandra T, Roger T. Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev 2003; 3:791-800.
5. Bernhagen J, Calandra T, Mitchell RA, et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993; 365:756-759.
6. Fu H, Luo F, Yang L, et al. Hypoxia stimulates the expression of macrophage migartion inhibitory factor in human vascular smooth muscle cells via HIF1alpha dependent pathways. BMC Cell Biol 2010; 11:1-12.
7. Simons D, Grieb G, Hristov M, et al. Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment. J Cell Mol Med 2011; 15:668-678.
8. Welford SM, Bedogni B, Gradin K, et al. HIF1alpha delays premature senescence through the activation of MIF. Genes Dev 2006; 20:3366-3371.
9. Bozza M, Satoskar AR, Lin G, et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999; 189:341-346.
10. Talos F, Mena P, Fingerle-Rowson G, et al. MIF loss impairs Myc-induced lymphomagenesis. Cell Death Differ 2005; 12:1319-1328.
11. Fingerle-Rowson G, Petrenko O, Metz CN, et al. The p53-dependent effects of macrophage migration inhibitory factor revelaed by gene targeting. Proc Natl Acad Sci U S A 2003; 100:9354-9359.
12. Taylor JA, Kuchel GA, Hedge P, et al. Null mutation for macrophage migration inhibitory factor (MIF) is associated with less agressive bladder cancer in mice. BMC Cancer 2007; 7:1-8.
13. Wilson JM, Coletta PL, Cuthbert RJ, et al. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 2005; 129:1485-1503.
14. Martin J, Duncan FJ, Keiser T, et al. Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet-B (UVB)-induced nonmelanoma skin cancer (NMSC). FASEB J 2009; 23:720-730.
15. Schulz R, Marchenko N, Holembowski L, et al. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med 2012; 209:275-289. This study identifies the mechanism ofMIF stabilization in cancer cells and also MIF as a new HSP90 client. This study confirms these results in a mouse breast cancer model.
16. Xu X, Wang B, Ye C, et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett 2008; 261:147-157.
17. Cludts S, Decaestecker C, Johnson B, et al. Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. Anticancer Res 2010; 30:3313-3319.
18. Wang XB, Tian XY, Li Y, et al. Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas. J Neurooncol 2012; 106:43-51.
19. Hira E, Ono T, Dhar DK, et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 2005; 103:588-598.
20. Yaddanapudi K, Putty K, Rendon BE, et al. Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. J Immunol 2013; 190:2984-2993. This study confirms that MIF suppresses tumour immune destruction and confirms metastatic potential of MIF in a mouse model.
21. Zhou Q, Yan X, Gershan J, et al. Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. J Immunol 2008; 181:1877-1886.
22. Simpson KD, Templeton DJ, Cross JV. Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J Immunol 2012; 189:5533-5540. This study confirms immune suppressive function of MIF in a metastatic breast cancer mouse model.
23. Bando H, Matsumoto G, Bando M, et al. Expression of macrophage migration inhibitory factor in human breast cancer: Association with nodal spread. Jpn J Cancer Res 2002; 93:389-396.
24. Choi J, Jung WH, Koo JS. Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry. Pathobiology 2013; 80:41-52.
25. Bini L, Magi B, Marzocchi B, et al. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 1997; 18:2832-2841.
26. Hagemann T, Robinson SC, Thompson RG, et al. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression and angiogenesis. Mol Cancer Therapy 2007; 6:1993-2002.
27. Meyer-Siegler KL, Iczkowski KA, Leng L, et al. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 2006; 177:8730-8739.
28. Meyer-Siegler KL, Iczkowski KA, Vera PL. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer 2005; 5:1-12.
29. Pyle ME, Korbonits M, Gueorguiev M, et al. Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. J Endocrinol 2003; 176:103-110.
30. Krockenberger M, Engel JB, Kolb J, et al. Macrophage migration inhibitory factor expression in cervical cancer. J Cancer Res Clin Oncol 2010; 136:651-657.
31. Cheng RJ, Deng WG, Niu CB, et al. Expression of macrophage migration inhibitory factor and CD74 in cervical squamous cell carcinoma. Int J Gynecol Cancer 2011; 21:1004-1012.
32. He XX, Chen K, Yang J, et al. Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med 2009; 15:1-10.
33. Meyer-Siegler KL, Leifheit EC, Vera PL. Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer 2004; 4:34.
34. He XX, Yang J, Ding YW, et al. Increased epithelial and serum expression of macrophage migartion inhibitory factor (MIF) in gastric cancer carcinogenesis. Gut 2006; 55:797-802.
35. Verjans E, Noetzel E, Bektas N, et al. Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer 2009; 9:1-18.
36. Binsky I, Haran M, Starlets D, et al. IL-8 secreted in a macrophage migrationinhibitory factor-and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci U S A 2007; 104:13408-13413.
37. Hagemann T, Wilson J, Kulbe H, et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 2005; 175:1197-1205.
38. Agarwal R, Whang DH, Alvero AB, et al. Macrophage migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol 2007; 196:e341-e345.
39. Meyer-Siegler KL. Increased stability of macrophage migration inhibitory factor (MIF) in DU-145 prostate cancer cells. J Interferon Cytokine Res 2000; 20:769-778.
40. Lue H, Thiele M, Franz J, et al. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF. Oncogene 2007; 26:5046-5059.
41. Bacher M, Schrader J, Thompson N, et al. Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumors cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am J Pathol 2003; 162:11-17.
42. Zhang C, Liang T, Song J, et al. Evaluation of macrophage migration inhibitory factor as an imaging marker for hepatocellular carcinoma in murine models. Scand J Gastroenterol 2011; 46:720-726.
43. Tomiyasu M, Yoshino I, Suemitsu R, et al. Quantification of macrophage migration inhibitory factor mRNA expression in nonsmall cell lung cancer tissues and its clinical signficance. Clin Cancer Res 2002; 8:3755-3760.
44. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nat Rev Mol Cell Biol 2010; 11:515-528.
45. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting teh dynamic HSP90 complex in cancer. Nat Rev 2010; 10:537-549.
46. Dai C, Santagata S, Tang Z, et al. Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. J Clin Invest 2012; 122:3742-3754.
47. Dai C, Whitesell L, Rogers AB, Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007; 130:1005-1018.
48. Xi C, Hu Y, Buckhaults P, et al. Heat shock factor Hsf1 cooperates with ErbB2 (Her2/Neu) protein to promote mammary tumorigenesis and metastasis. J Biol Chem 2012; 287:35646-35657.
49. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
50. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: Oncogene and nononcogene addiction. Cell 2009; 136:823-837.
51. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-674.
52. Mitchell RA, Liao H, Chesney J, et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response. Proc Natl Acad Sci U S A 2002; 99:345-350.
53. Nemajerova A, Moll UM, Petrenko O, Fingerle-Rowson G. Macrophage migration inhibitory factor coordinates DNA damage response with the proteasomal control of the cell cycle. Cell Cycle 2007; 6:1030-1034.
54. Nemajerova A, Mena P, Fingerle-Rowson G, et al. Impaired DNA damage checkpoint response in MIF-deficient mice. EMBO J 2007; 26:987-997.
55. Petrenko O, Fingerle-Rowson G, Peng T, et al. Macrophage migration inhibitory factor deficiency is associated with altered cell growth and reduced susceptibility to Ras-mediated transformation. J Biol Chem 2003; 278:11078-11085.
56. Petrenko O, Moll UM. Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Molecular cell 2005; 17:225-236.
57. Shi X, Leng L, Wang T, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 complex. Immunity 2006; 25:595-606.
58. Oda S, Oda T, Nishi K, et al. Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent manner. PLoS One 2008; 3:e2215; 1-5.
59. Winner M, Koong AC, Rendon BE, et al. Amplification of tumor hypoxic response by macrophage migration inhibitory factor stabilization. Cancer Res 2007; 67:186-193.
60. Lin EY, Li JF, Gnatovskiy L, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006; 66:11238-11246.
61. Funamizu N, Hu C, Lacy C, et al. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. Int J Cancer 2013; 132:785-794. This study shows for the first time that MIF can induce EMT.
62. Fingerle-Rowson G, Kaleswarapu DR, Schlander C, et al. A Tautomerase-null macrophage migration inhibitory factor (MIF) gene knock-in mouse model reveals that protein interaction and not enzymatic activity mediate MIFdependent growth regulation. Mol Cell Biol 2009; 29:1922-1932.
63. Choudhary S, Hegde P, Pruitt JR, et al. Macrophage migratory inhibitory factor (MIF) promotes bladder cancer progression via increasing proliferation and angiogenesis. Carcinogenesis 2013. [Epub ahead of print]
64. Calandra T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6:164-170.
65. Hussain F, Freissmuth M, Volkel D, et al. Human antimacrophage migration inhibitory factor antibodies inhibit growth of human prostate cancer cells in vitro and in vivo. Mol Cancer Ther 2013; 12:1223-1234.
66. Schulz R, Dobbelstein M, Moll UM. HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates. Oncoimmunology 2012; 1:1425-1426.
67. Modi S, Stopeck A, Linden H, et al. HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011; 17:5132-5139.
68. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425:407-410.
69. Moulick K, Ahn JH, Zong H, et al. Affinity-based proteomics reveal cancerspecific networks coordinated by Hsp90. Nat Chem Biol 2011; 7:818-826.